Find information on thousands of medical conditions and prescription drugs.

Cotinine

Cotinine is a break-down product of nicotine from cigarette smoke. Cotinine typically remains in the blood between 48 and 96 hours. The level of cotinine in the blood is proportionate to the amount of exposure to tobacco smoke, so it is a valuable indicator of tobacco smoke exposure, including secondary smoke. Women who smoke menthol cigarettes retain cotinine in the blood for a longer period. Race may also play a role, as blacks routinely register higher blood cotinine levels than whites. more...

Home
Diseases
Medicines
A
B
C
Cabergoline
Caduet
Cafergot
Caffeine
Calan
Calciparine
Calcitonin
Calcitriol
Calcium folinate
Campath
Camptosar
Camptosar
Cancidas
Candesartan
Cannabinol
Capecitabine
Capoten
Captohexal
Captopril
Carbachol
Carbadox
Carbamazepine
Carbatrol
Carbenicillin
Carbidopa
Carbimazole
Carboplatin
Cardinorm
Cardiolite
Cardizem
Cardura
Carfentanil
Carisoprodol
Carnitine
Carvedilol
Casodex
Cataflam
Catapres
Cathine
Cathinone
Caverject
Ceclor
Cefacetrile
Cefaclor
Cefaclor
Cefadroxil
Cefazolin
Cefepime
Cefixime
Cefotan
Cefotaxime
Cefotetan
Cefpodoxime
Cefprozil
Ceftazidime
Ceftriaxone
Ceftriaxone
Cefuroxime
Cefuroxime
Cefzil
Celebrex
Celexa
Cellcept
Cephalexin
Cerebyx
Cerivastatin
Cerumenex
Cetirizine
Cetrimide
Chenodeoxycholic acid
Chloralose
Chlorambucil
Chloramphenicol
Chlordiazepoxide
Chlorhexidine
Chloropyramine
Chloroquine
Chloroxylenol
Chlorphenamine
Chlorpromazine
Chlorpropamide
Chlorprothixene
Chlortalidone
Chlortetracycline
Cholac
Cholybar
Choriogonadotropin alfa
Chorionic gonadotropin
Chymotrypsin
Cialis
Ciclopirox
Cicloral
Ciclosporin
Cidofovir
Ciglitazone
Cilastatin
Cilostazol
Cimehexal
Cimetidine
Cinchophen
Cinnarizine
Cipro
Ciprofloxacin
Cisapride
Cisplatin
Citalopram
Citicoline
Cladribine
Clamoxyquine
Clarinex
Clarithromycin
Claritin
Clavulanic acid
Clemastine
Clenbuterol
Climara
Clindamycin
Clioquinol
Clobazam
Clobetasol
Clofazimine
Clomhexal
Clomid
Clomifene
Clomipramine
Clonazepam
Clonidine
Clopidogrel
Clotrimazole
Cloxacillin
Clozapine
Clozaril
Cocarboxylase
Cogentin
Colistin
Colyte
Combivent
Commit
Compazine
Concerta
Copaxone
Cordarone
Coreg
Corgard
Corticotropin
Cortisone
Cotinine
Cotrim
Coumadin
Cozaar
Crestor
Crospovidone
Cuprimine
Cyanocobalamin
Cyclessa
Cyclizine
Cyclobenzaprine
Cyclopentolate
Cyclophosphamide
Cyclopropane
Cylert
Cyproterone
Cystagon
Cysteine
Cytarabine
Cytotec
Cytovene
Isotretinoin
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Several variable factors, such as menthol cigarette preference and puff size, suggest that the explanation for this difference may be more complex than gender or race.

Drug tests can detect cotinine in the blood, urine, or saliva.

The word 'cotinine' is an anagram of 'nicotine'.

Chemical Name: (S)-1-methyl-5-(3-pyridinyl)-2-Pyrrolidinone

Synonymes: Cotinine; (-)-Cotinine; 1-Methyl-5-(3-pyridinyl)-2-pyrrolidinone;

Chemical Formula: C10H12N2O

Molar mass: 176.22 g/mol

There is some research being done on the memory and brain-function improving effects of cotinine. Cotinine (as well as nicotine) appears to improve memory function, and prevent cell death. For this reason it has been studied for effectiveness in treating Alzheimer's disease.

Read more at Wikipedia.org


[List your site here Free!]


Urinary levels of nicotine & cotinine in tobacco users
From Indian Journal of Medical Research, 9/1/03 by Behera, Digambar

Background & objectives: Of the various biochemical markers used to validate the smoking status of a person, nicotine and continine are considered as good markers for both active and passive smoking. In the present study an attempt was made to estimate urinary levels of nicotine and cotinine in healthy individuals from north India using different types of tobacco to identify and validate the smoking status.

Methods: Twenty four hour urine sample of 130 healthy volunteers (smokers=70, passive smokers=20, tobacco chewers=20, non smokers=20) were analyzed by high-pressure liquid chromatography (HPLC) assay. Smokers were divided into different groups, viz., cigarette, bidi and hooka smokers.

Results: The mean values of nicotine (ng/ml) and cotinine (ng/ml) in urine were highest in cigarette smokers (nicotine=703.50±304.34; cotinine=2736.20±983.29), followed by hooka smokers (nicotine 548.0±103.47 and cotinine 2379.0±424.25), and bidi smokers (nicotine=268.53±97.62, cotinine=562.60±249.38). There was no correlation of nicotine or cotinine values with smoking index. In passive smokers (nicotine=109.75±22.33, cotinine=280.75±86.30) and in nonsmokers, the values were much lower (nicotine=55.00±13.71, cotinine=7.30±2.47) compared to smokers. In tobacco chewers, the values for nicotine and cotinine were 447.75±45.09 and 2178.30±334.29 respectively.

Interpretation & conclusion: all forms of tobacco users had significantly higher values compared to passive smokers and nonusers. Thus, cotinine and nicotine levels in urine may be considered as good indicators to assess the exposure to tobacco in our population.

Key words Cotinine - nicotine - smokers - tobacco

In India, tobacco is consumed both in smoking and non-smoking forms. Smoking forms include cigarette, bidi, hooka and chutta (a reverse form of smoking in which smoking is done with the burning end inside the mouth)1 ; tobacco chewing is the main non-smoking form of tobacco use.

Self reported smoking rates are likely to give a substantial underestimate of the true prevalence of smoking and as many as one-sixth of smokers who claimed to be nonsmokers, actually may be positive for urinary cotinine2, which could lead to an underestimation of the effect of smoking on the course of disease and could prejudicially affect decisions on patient management.

A number of biochemical markers like thiocynate, nicotine, cotinine and carbon monoxide in the expired air and carboxyhaemoglobin in blood have been used to validate claims of non-smoking3,4. Levels of thiocynate and carbon monoxide/carboxyhaemoglobin5 are easier to determine but can be raised through exposures unrelated to smoking such as traffic emissions and diet. Cotinine is possibly the best marker for situations where accuracy is paramount6-11.

Cotinine is a major metabolite of nicotine but its level in the blood is not a good marker of nicotine content of blood. In contrast, urinary excretion of cotinine is a good marker as it is less influenced by the flow of urine and pH. For study of nicotine and cotinine levels, it is preferable to have non-invasive methods. The choice of body fluids for cotinine assay in smoking studies should depend on practical rather than pharmokinetics considerations. Cotinine, which is a major metabolite of nicotine is stable in body fluids, has a long half-life, low plasma protein binding (2.6%), and dose independent disposition kinetics. These factors make cotinine a good marker for estimating both active and passive exposure to tobacco smoke12.

Although information about the continine and nicotine values is available for cigarette smokers from other ethnic groups, such information in the bidi and hooka smokers and tobacco chewers is not available. In the present study, we estimated the amount of nicotine and cotinine excretion in urine in a group of healthy individuals from north India who were users of tobacco in different forms and also in nonsmokers and compared the values amongst different groups of tobacco users.

Material & Methods

The study was conducted over a period of one year (1999-2000) in the Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh and included 130 healthy north Indian volunteers of either sex who were further divided into tobacco user and non-tobacco user groups. The user group included cigarette smokers (30), bidi smokers (30), hooka smokers (10) and tobacco chewers (20). The other group had passive smokers (20) and 20 nonsmokers who had not been exposed to the tobacco smoke or had not ever chewed tobacco. All the 130 volunteers were attendants of the patients, and were apparently healthy, asymptomatic and not using any drug. A smoker was a person who smoked one cigarette/one bidi/hooka smoking/per day for at least one year and the tobacco chewer was one who was chewing tobacco for at least one year in most of the days. A passive smoker was one whose family members were smokers. A nonsmoker was a person who had never been exposed to the tobacco smoke either actively or passively in the home or place of work at least one week prior to the study. Smoking index was calculated as number of bidis/cigarettes smoked per day x number of years of smoking. Quantification of hooka smoking and tobacco chewing was not possible.

The individual was instructed to collect 24 h urine in a clean glass bottle. Urine collection was started at 8 am in the morning after passing and discarding the first urine and collecting the whole urine till 8 am of the next morning. The total volume was noted and after mixing the urine properly, the sample was taken for testing.

Source of chemicals/reagents: Chemicals used in the study were procured from Sigma Chemical Company, USA. For HPLC, HPLC grade chemicals were procured from Ranbaxy Laboratories Ltd., India.

High pressure liquid choromatography (HPLC) assay was used to estimate the cotinine and nicotine levels13,14. For extraction, 1 ml of urine sample was taken and added to 1 ml of trichloacetic acid (TCA), kept in vortex for 30 seconds and the mixture was centrifuged at 1100 g (10-20 min). The supernatant was transferred to another tube. To the supernatant, 0.5 ml of KOH and 6 ml of dichloro methane (DCM) were added, shaken in a water bath for 30 seconds, followed by centrifugation at 1100g for 10 min. In the upper layer, 3 ml of HCl (50 mmol) was added and was shaken for 30 seconds followed by centrifugation. To the upper layer, 0.5 ml KOH and 5 ml of DCM were added and shaken for 30 seconds, and centrifuged again. To the upper layer, 200 µl of methanolic HCl was added and dried under N2 gas, 30 µl of it was injected in the HPLC column and values of nicotine and cotinine were read at the wavelength of 256 and 262nm respectively. The assay was performed using reversed phase C-18 ion pair column in an isocratic mode. The HPLC unit consisted of a pump (model 510, Waters, India), a variable-wavelength ultraviolet detector (model 481, Waters, India) with a deuterium lamp. We used a 15 x 0.2 cm column of ODS Hypersil, 3 µm particle size, from Shandon Inc., Pittsburgh, PA, an injector with a 200 µl loop. Mobile phase used was a mixture of citrate and dibasic phosphate (30 mmol of each/litre) containing 1 mmol of sodium heptanesulphonate and 50 ml of acetonitrite per litre (pH 6.1). The flow rate of the mobile phase was 0.3 ml/min and the column pressure was 3000 psi. Respective nicotine and cotinine standards (Sigma, USA) were used (20 nmol/200 µl methanol).

Nonparametric methods were used for group comparisons, using Kruskal-Wallis H test for multiple independent group and Mann Whitney U test for two independent groups. Correlations between nicotine and cotinine values were assessed using Pearson's correlation coefficient. Linear regression analysis was performed to assess if cumulative smoking index was significantly associated with nicotine and/or cotinine levels. For all statistical procedures, significance was assessed at P

Results

All smokers and tobacco chewers were males, their age range 25-65 yr. In the group of passive smokers, there were 19 females (22-40yr) and one male (40yr). There were 8 females (26-50 yr) and 12 males (20-60yr) in the non smokers group. Nicotine and cotinine excretion in urine was maximum in cigarette smokers followed by hooka smokers, tobacco chewers, bidi smokers and passive smokers (Table). The amount was negligible in non smokers. The smoking index in cigarette smokers was found to be 90±39.39 and the same for bidi smoker was 172±69.25. No correlation could be established with smoking index in both cigrette and bidi smokers as there was a wide scatter of values (R^sup 2^ = 0.002 for nicotine and 0.137 for continine, for both groups of smokers).

Correlation of nicotine to cotinine was statistically significant in cigarette smokers (r=0.5501, P0.05) and in tobacco chewers (r=-0.409, P>0.05) a non-significant negative correlation was obtained.

Discussion

Nicotine and cotinine levels have earlier been used to validate the smoking status of an individual15,16. These biomarkers have also been used in epidemiological studies8,11,17,18,, to assess the effects of tobacco use on human health19,20, as measures to estimate the exposure to environmental tobacco smoking, and for assessment of the efficacy of interventional methods on cessation of smoking21. While studies on nicotine and cotinine levels in cigarette smokers as well as those for passive smoking in other ethnic groups are well documented, information on bidi, hooka and tobacco used in non smoking forms (tobacco chewing) is lacking. This is because of the fact that these peculiar forms of tobacco use are confined to certain parts of the world only. Other forms of smokeless tobacco use include snus (Snuff) in Sweden, and toombak by Sudanese people22,23. Hooka smoking prevalent in parts of India and Pakistan, is akin to the water-pipes (narguila) used mostly in Middle-East countries. Macaron et al24 reported similar urinary levels of cotinine for the smokers of cigarette (median 30 cigarettes per day) and narguila (median 2 pipes per day or around 40 g of tobacco). In the present study, hooka smokers has lower values for both nicotine and cotinine compared to cigarette smokers. It is possible that use of water pipes, through which the smoke passes, removes some amount of nicotine. Oral intake of tobacco by chewing also increased the excretion as nicotine can be absorbed from oral mucosa. Bidi smokers had a lower value of urinary nicotine excretion than that observed in tobacco chewers and hooka smokers, though was significantly higher compared to non smokers as well as passive smokers. Bidi contains larger amount of nicotine compared to cigarette when compared for g to g1. Though the bidi smokers have higher smoking index, the lower values of nicotine and cotinine may be explained by the fact that one cigarette is not equivalent to one bidi, thus the nicotine intake in terms of g will be different in both groups. Other variables like individual variation, and dietary intake of nicotine may also influence the values of nicotine and cotinine excretion25-27, though we have not tried to find out these factors in the present study. The mean age of individuals in all the groups was comparable, except in hooka smokers because persons with this form of smoking are usually older and at present, younger population does not prefer this form of tobacco use. There is no effect of age or sex on the nicotine or cotinine excretion7,28. Thus, the age variation may not be an attributable factor for the variation seen. The adverse effects of passive smoke exposure on the respiratory tract are well established19,29. One of the most frequently used biomarkers for exposure to environmental tobacco smoke is cotinine in body fluids18. We found higher values of urinary nicotine and cotinine in passive smokers compared to non smokers in the present study. Our results indicate that both nicotine and cotinine may be useful markers for identifying and validating the smoking status in Indian population.

Thus, we conclude that nicotine and cotinine levels in urine may be useful markers to assess the effect of different types of tobacco use in our population.

References

1. Malik SK, Behera D. Chemistry of tobacco and tobacco smoke in chutta - a homemade cigar: a preliminary study. Int J Clin Pharmacol Ther Toxicol 1985; 23 : 604-5.

2. Apseioff G, Ashton HM, Friedman H, Gerber N. The importance of measuring cotininc levels to identify smokers in clinical trials. Clin Pharmacol Ther 1994; 56 : 460-2.

3. Pojer R, Whitefield .IB, Poulos V, Eckhard IF, Richmond R, Hensley WJ. Carboxyhaemoglobin, cotinine, and thiocyanate assay compared for distinguishing smokers from non-smokers. Clin Chem 1984; 30 : 1377-80.

4. Jarvis MJ, Tunstall-Pedoc H, Feyerabend C, Vesey C, Soloojee Y. Comparison of tests used to distinguish smokers from nonsmokers. Am J Public Health 1987; 77 : 1435-8.

5. BeheraD, Dash S, Dinakar M. Blood Carboxyhaemoglobin levels in Indian bidi and cigarette smokers. Respiration 1991; 58 : 26-8.

6. Ji AJ, Lawson GM, Anderson R, Dale LC, Croghan IT, Hurt RD. A new gas chromatography-mass spectrometry method for simultaneous determination of total and free trans-3'-hydroxycotinine and cotinine in the urine of subjects receiving transdermal nicotine. Clin Chem 1999; 45 : 85-91.

7. Hansen AM, Garde AH, Christensen JM, Eller N, Knudsen LE, Heinrich-Ramm R. Reference interval and subject variation in excretion of urinary metabolities of nicotine from non-smoking healthy subjects in Denmark. Clin Chim Acta 2001 ; 304 : 125-32.

8. Trout D, Decker J, Mueller C, Bernert JT, Pirkle J. Exposure of casino employees to environmental tobacco smoke. J Occup Environ Med 1998; 40 : 270-6.

9. Bono R, Russo R, Arossa W, Scursatone E, Gilli G. Involuntary exposure to tobacco smoke in adolescents: urinary cotinine and environmental factors. Arch Environ Health 1996; 51 : 127-31.

10. Jacob P3rd, Yu L, Shulgin AT, Benowitz NL. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health 1999; 89 : 731-6.

11. Apseloff G, Ashton MM, Friedman H, Gerber N. The importance of measuring cotinine levels to identify smokers in clinical trials, din Pharmacol Ther 1994; 56 : 460-2.

12. Curvall M, Elwin CK, Kazemi-Vala E, Warholm C, Enzell CR. The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur J Clin Pharmacol 1990; 38 : 281-7.

13. Feyerabend C, Russell MA. Rapid gas-liquid Chromatographic determination of cotinine in biological fluids. Analyst 1980; 105 : 998-1001.

14. Mengen N, Mengen M, Gas-liquid Chromatographic determination of nicotine and cotinine in plasma. Clin Chem 1978; 24 : 50-3.

15. Byrd GD, Chang KM, Greene JM, deBethizy JD. Evidence for urinary excretion of glucuronide conjugates of nicotine, cotinine, and trans-3' - hydroxycotinine in smokers. Drug Metab Dispos 1992; 20 : 192-7.

16. Lequant NT, Roussel G, Roche D, Migueres ML, Chretien J, Ekindjian OG. Urine collection for nicotine and cotinine measurement in study on nicotine addicts. Pathol Biol (Paris) 1994; 42 : 191-6.

17. Barrueco M, Cordovilla R, Hernandez-Mezquita MA, Gonzalez JM, de Castro J, Rivas P, et al. The truthfulness of the answers of children, adolescents and young people to surveys on tobacco consumption conducted in schools. MedClin (Bare) 1999; 112 : 251-4.

18. Scherer G, Richter E. Biomonitoring exposure to environmental tobacco smoke (ETS) : a critical reappraisal. Hum Exp Toxicol 1997; 16 : 449-59.

19. Carey IM. Cook DG, Strachan DR The effects of environmental tobacco smoke exposure on lung function in a longitudinal study of British adults. Epidemiology 1999; 10 : 319-26.

20. de Waard F, Kemmeren JM, van Ginkel LA, Stoiker AA. Urinary cotinine and lung cancer risk in a female cohort. Br J Cancer 1995; 72 : 784-7.

21. Lawson GM, Hurt RD, Dale LC, Offord KP. Croghan IT, Schroeder DR, et al. Application of urine nicotine and cotinine excretion rates to assessment of nicotine replacement in light, moderate, and heavy smokers undergoing transdermal therapy. J Clin Pharmacol 1998; 38 : 510-6.

22. Idris AM, Ibrahim SO, Vasstrand RN, Johannessen AC, Lillehaug JR, Magnusson B, et al. The Swedish snus and the Sudanese toombak: are they different? Oral Oncol 1998; 34 : 558-66.

23. Henningfield JE, Fagerstrom KO. Swedish Match Company. Swedish snus and public health: a harm reduction experiment in progress? TbA Control 2001; 10 : 253-7.

24. Macaron C, Macaron Z, Maalouf MT. Macaron N, Moore A. Urinary cotinine in narguila or chicha tobacco smokers. J Med Liban 1997; 45 : 19-20.

25. Hecht SS, Carmella SG, Murphy SE. Effects of watercress consumption on urinary metabolites of nicotine in smokers. Cancer Epidemiol Biomarkers Prev 1999; 8 : 907-13.

26. Davis RA, Stiles MF, DeBethizy JD, Reynolds JH. Dietary nicotine: a source of urinary cotinine. Food Chem Toxicol 1991; JP : 821-7.

27. Benowitz NL, Perez-Stable EJ, Hong I, Modin G, Herrera B, Jacob P3rd. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999; 291 : 1196-203.

28. Molander L, Hansson A, Lunell E. Pharmacokinctics of nicotine in healthy elderly people. Clin Pharmacol Ther 2001; 69 : 57-65.

29. Weiss ST, Tager IB, Schenker M, Speizcr FE. The health effects of involuntary smoking. Am Rev Respir Dis 1983; 128 : 933-42.

Digambar Behera, Rajan Uppal & Sidharath Majumdar*

Department of Pulmonary Medicine & * Experimental Medicine & Biotechnology Postgraduate Institute of Medical Education & Research, Chandigarh, India

Received September 6, 2002

Reprint reque sis : Dr D. Behera, Professor, Department of Pulmonary Medicine, Postgraduate Institute of Medical Education & Research, Chandigarh 160012, India

e-mail : dbehera@glide.net.in

Copyright Indian Council of Medical Research Sep 2003
Provided by ProQuest Information and Learning Company. All rights Reserved

Return to Cotinine
Home Contact Resources Exchange Links ebay